Bettina Balint1,2,3, Hans-Michael Meinck3. 1. Sobell Department of Motor Neuroscience and Movement Disorders UCL Institute of Neurology Queen Square, London UK. 2. Neuroimmunology Group, Nuffield Department of Clinical Neurosciences John Radcliffe Hospital Oxford UK. 3. Department of Neurology University Hospital Heidelberg Germany.
Abstract
BACKGROUND: Stiff person spectrum disorders (SPSD) are a group of rare conditions clinically characterized by stiffness, spasms, and heightened stimulus sensitivity. They also share a spectrum of antibodies. METHODS: We reviewed the literature and our own experience with the aim of providing a practical approach to the treatment of SPSD. RESULTS: Because of the rarity of SPSD, there is little evidence to guide treatment decisions. The treatment of SPSD is based on the triad of symptomatic treatment, immunotherapy, and tumor treatment where appropriate. Moreover, the management involves continuous and appropriate monitoring of the symptoms of the disease, its autoimmune associations, and potential treatment side effects. CONCLUSIONS: Here we delineated a pragmatic treatment approach to SPSD, based on our experience and existing literature. We also highlighted how our understanding of neuronal antibodies and their implications reflects on management considerations.
BACKGROUND: Stiff person spectrum disorders (SPSD) are a group of rare conditions clinically characterized by stiffness, spasms, and heightened stimulus sensitivity. They also share a spectrum of antibodies. METHODS: We reviewed the literature and our own experience with the aim of providing a practical approach to the treatment of SPSD. RESULTS: Because of the rarity of SPSD, there is little evidence to guide treatment decisions. The treatment of SPSD is based on the triad of symptomatic treatment, immunotherapy, and tumor treatment where appropriate. Moreover, the management involves continuous and appropriate monitoring of the symptoms of the disease, its autoimmune associations, and potential treatment side effects. CONCLUSIONS: Here we delineated a pragmatic treatment approach to SPSD, based on our experience and existing literature. We also highlighted how our understanding of neuronal antibodies and their implications reflects on management considerations.
Entities:
Keywords:
antibodies; immunotherapy; progressive encephalomyelitis with rigidity and myoclonus; stiff limb syndrome; stiff person spectrum disorders; stiff person syndrome; treatment
Authors: C A Vedeler; J C Antoine; B Giometto; F Graus; W Grisold; I K Hart; J Honnorat; P A E Sillevis Smitt; J J G M Verschuuren; R Voltz Journal: Eur J Neurol Date: 2006-07 Impact factor: 6.089
Authors: Bettina Balint; Sven Jarius; Simon Nagel; Uwe Haberkorn; Christian Probst; Inga Madeleine Blöcker; Ramona Bahtz; Lars Komorowski; Winfried Stöcker; Andreas Kastrup; Martin Kuthe; Hans-Michael Meinck Journal: Neurology Date: 2014-04-02 Impact factor: 9.910